Rituximab combined with tacrolimus induction + tacrolimus maintenance ( DrugBank: Rituximab, Tacrolimus )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
222一次性ネフローゼ症候群1

222. 一次性ネフローゼ症候群


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05532111
(ClinicalTrials.gov)
September 1, 20221/9/2022Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical TrialEfficacy and Safety of Rituximab Combined With Tacrolimus in the Treatment of Intermediate-to-high Risk Primary Membranous Nephropathy: A Randomized Clinical TrialEfficacy and SafetyDrug: Rituximab combined with tacrolimus induction + rituximab maintenance;Drug: Rituximab combined with tacrolimus induction + tacrolimus maintenance;Drug: Glucocorticoid combined with cyclophosphamide induction + maintenanceRenJi HospitalNULLNot yet recruiting18 Years75 YearsAll60N/ANULL